R&D Trends

NIHR launches online neurodegenerative disease research showcase

Wednesday, September 4, 2013 12:01 PM

To mark the start of World Alzheimer’s Month, the National Institute for Health Research (NIHR) is showcasing clinical research that could bring new hope to dementia patients and their families, and those with other neurodegenerative diseases, with the launch of www.FocusOnDementia.nihr.ac.uk. 

More... »

Wellcome Trust, KU Leuven, Janssen collaborate

Wednesday, September 4, 2013 11:53 AM

Wellcome Trust, Janssen and KU Leuven are collaborating for dengue antiviral drugs. The collaboration will build on an existing three-year drug discovery program at the Rega Institute and the Center for Drug Design and Discovery (CD3) at KU Leuven, supported by a Wellcome Trust Seeding Drug Discovery Award.

More... »

Mount Sinai, Exosome Diagnostics partner

Friday, August 30, 2013 02:29 PM

The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics are collaborating on the R&D of real-time nucleic acid-based body-fluid diagnostics to advance personalized medicine. Exosome will provide technical and development support to Mount Sinai researchers along with early access to proprietary technology products upgrades. The five-year agreement will allow the companies to establish targeted research and biomarker discovery programs in oncology and inflammation. Exosome anticipates pursuing commercial development and FDA review of successful validations for in vitro diagnostics.

More... »

Idera Pharmaceuticals, NCI collaborate

Friday, August 30, 2013 02:25 PM

Idera Pharmaceuticals entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate the company’s Toll-like receptor (TLR) antagonists as a potential approach to the treatment of certain genetically defined B-cell lymphomas.

More... »

ObsEva, Merck Serono ink license agreement

Friday, August 30, 2013 02:23 PM

ObsEva, a Swiss-based, specialty biopharmaceutical company, signed a licensing agreement with Merck Serono, the biopharmaceutical division of Germany-based Merck, granting ObsEva worldwide development and commercialization rights to certain Merck Serono compounds for preterm labor. The details of the agreement were not disclosed. The funding will allow ObsEva to undertake the development of these compounds.

More... »

International Stem Cell, Duke collaborate on Parkinson's disease

Friday, August 30, 2013 02:22 PM

International Stem Cell (ISCO), a California-based biotechnology company developing novel stem cell-based therapies, has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's neural stem cell product.

More... »

Zealand, Eli Lilly collaborate on peptide drug R&D

Friday, August 30, 2013 02:20 PM

Zealand Pharma, a Denmark-based biotechnology company, announced an exclusive peptide drug R&D collaboration with Eli Lilly.

More... »

Evotec, Jain Foundation extend research collaboration

Thursday, August 29, 2013 11:00 AM

Evotec, a drug discovery alliance and development partnership company, and privately funded nonprofit the Jain Foundation have extended and expanded their research collaboration leveraging Evotec's assay development and screening capabilities to support the Jain Foundation's goals of understanding and curing dysferlinopathy.

More... »

Covidien opens Center of Innovation Korea

Thursday, August 29, 2013 09:00 AM

Covidien, a global provider of healthcare products, has opened the Covidien Center of Innovation Korea (CCI Korea), its first R&D and training and education center in Korea.

More... »

Roche, Chugai’s schizophrenia drug forecast to earn $1.5b in 2022

Wednesday, August 28, 2013 12:43 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, has found Roche/Chugai’s glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the U.S. and Europe in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects bitopertin will garner nearly $1.5 billion in major-market sales in 2022.

More... »